Quest Diagnostics has introduced a new flow cytometry measurable residual disease (MRD) blood test for myeloma, a cancer arising from abnormal plasma cells. The test aims to enhance ultra-sensitive ...

New test as sensitive as next-generation sequencing, and provides five-day specimen stability to support nationwide testing SECAUCUS, N.J., Feb. 2, 2026 /PRNewswire/ -- Quest Diagnostics (DGX), a ...

CHICAGO — The use of a clinically validated flow cytometry test can assess type 1 and type 2 interferon activity in children with various pediatric inflammatory diseases to evaluate and monitor their ...

Immunophenotyping helps doctors diagnose and classify specific blood cell cancers, like leukemia and lymphoma, as well as other diseases. Immunophenotyping is a lab test doctors use to identify and ...

Accurate and timely diagnosis of inborn errors of immunity (IEI) is essential for improving patient outcomes. Flow cytometry is widely recommended for robust and sensitive IEI screening; however, no ...

"Our Flow Cytometry MRD for Myeloma test harnesses cutting-edge science and technology to deliver ultrasensitive insights from a noninvasive blood test, thereby improving care and value for patients ...

SECAUCUS, N.J., Feb. 2, 2026 /PRNewswire/ --Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the launch of a novel blood test that uses advanced ...